Cancer immunotherapy vaccine combination

This page covers all Cancer immunotherapy vaccine combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway.

Targets

Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway

Phase 3 pipeline (1)

• HyperAcute-Pancreas Immunotherapy · NewLink Genetics Corporation · Oncology
  HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor.

Patent intelligence

• cancer immunotherapy vaccine combination patent landscape — aggregated cliff calendar, attackable patents, originator estates